Terns Pharmaceuticals, Inc. SG&A Expenses

SG&A Expenses of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative


Highlights and Quick Summary

  • SG&A Expenses for the quarter ending March 31, 2022 was $5.69 Million (a 5.04% increase compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses increased by 17.13%
  • Annual SG&A Expenses for 2021 was $19.5 Million (a 117.31% increase from previous year)
  • Annual SG&A Expenses for 2020 was $9 Million (a 3.84% increase from previous year)
  • Annual SG&A Expenses for 2019 was $8.66 Million (a 122.07% increase from previous year)
  • Twelve month SG&A Expenses ending March 31, 2022 was $20.7 Million (a 6.71% increase compared to previous quarter)
  • Twelve month trailing SG&A Expenses increased by 52.29% year-over-year
Trailing SG&A Expenses for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$20.7 Million $19.4 Million $15 Million $13.6 Million
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of Terns Pharmaceuticals, Inc.

Most recent SG&A Expensesof TERN including historical data for past 10 years.

Interactive Chart of SG&A Expenses of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $5.69
2021 $5.42 $4.72 $4.86 $4.39 $19.55
2020 $1.0 $3.33 $2.49 $2.18 $9.0
2019 $2.39 $8.66
2018 $3.9

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.